 Early interim-PET after two courses of chemotherapy is a powerful outcome predictor in advanced-stage Hodgkin Lymphoma HL patients treated with adriamycin doxorubicin, bleomycin, vinblastine and dacarbazine ABVD. Two-year Progression Free Survival of PET-2 positive patients is only 12, but the optimal treatment for this patient subset is still unknown. 